(CTMX) CytomX Therapeutics - Overview
Stock: Antibody-Drug Conjugate, T-Cell Engager, Probody Cytokine, Bispecific Antibody
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 108% |
| Relative Tail Risk | -22.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.71 |
| Alpha | 475.51 |
| Character TTM | |
|---|---|
| Beta | 2.177 |
| Beta Downside | 1.380 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.59% |
| CAGR/Max DD | 0.34 |
Description: CTMX CytomX Therapeutics December 29, 2025
CytomX Therapeutics (NASDAQ:CTMX) is an oncology-focused biopharma that leverages its conditional-activation PROBODY platform to create antibodies that become active only within the tumor microenvironment, aiming to broaden the therapeutic window for ADCs, T-cell engagers, and cytokine therapies.
Current lead assets include CX-904 (an EGFR-directed T-cell-engaging bispecific), CX-2051 (a conditional ADC against EpCAM for colorectal and other epithelial cancers), and CX-801 (a PROBODY-masked interferon-α2b cytokine). The pipeline also contains CX-2029 (CD71-targeted ADC) and a PROBODY version of non-fucosylated ipilimumab (BMS-986288) in collaboration with Bristol Myers Squibb.
Strategic partnerships span Amgen, Astellas, Regeneron, Moderna, and a clinical-trial supply agreement with Merck to test CX-801 alongside KEYTRUDA (pembrolizumab). These collaborations provide non-dilutive funding and de-risk development, but the company remains early-stage with no commercial products.
As of the latest filing (Q3 2024), CytomX reported cash and equivalents of roughly $140 million, giving it an estimated 18-month runway at current burn rates; the biotech sector’s ADC market is projected to grow at a CAGR of ~15% through 2030, a macro driver that could lift the valuation of conditional-activation technologies if clinical milestones are met.
For anyone building a deeper thesis on CTMX, a quick look at ValueRay’s analyst notes may surface additional quantitative insights worth exploring.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 28.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA 18.16 > 1.0 |
| NWC/Revenue: 95.21% < 20% (prev 3.91%; Δ 91.30% < -1%) |
| CFO/TA -0.46 > 3% & CFO -72.3m > Net Income 28.0m |
| Net Debt (-28.6m) to EBITDA (26.1m): -1.09 < 3 |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (165.0m) vs 12m ago 93.66% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 76.46% > 50% (prev 91.10%; Δ -14.65% > 0%) |
| Interest Coverage Ratio: -7.26 > 6 (EBITDA TTM 26.1m / Interest Expense TTM -3.42m) |
Altman Z'' -15.00
| A: 0.68 (Total Current Assets 149.2m - Total Current Liabilities 41.0m) / Total Assets 158.3m |
| B: -4.31 (Retained Earnings -682.4m / Total Assets 158.3m) |
| C: 0.17 (EBIT TTM 24.8m / Avg Total Assets 148.6m) |
| D: -13.41 (Book Value of Equity -682.3m / Total Liabilities 50.9m) |
| Altman-Z'' Score: -22.54 = D |
Beneish M -2.93
| DSRI: 0.54 (Receivables 1.63m/3.35m, Revenue 113.6m/126.6m) |
| GMI: 1.00 (GM 99.33% / 98.88%) |
| AQI: 0.82 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 0.90 (Revenue 113.6m / 126.6m) |
| TATA: 0.63 (NI 28.0m - CFO -72.3m) / TA 158.3m) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of CTMX shares?
Over the past week, the price has changed by -0.35%, over one month by +36.96%, over three months by +35.32% and over the past year by +551.72%.
Is CTMX a buy, sell or hold?
- StrongBuy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CTMX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 49.9% |
| Analysts Target Price | 8.5 | 49.9% |
| ValueRay Target Price | 6.1 | 7.6% |
CTMX Fundamental Data Overview January 31, 2026
P/E Forward = 14.2045
P/S = 8.1712
P/B = 9.0564
P/EG = -1.8
Revenue TTM = 113.6m USD
EBIT TTM = 24.8m USD
EBITDA TTM = 26.1m USD
Long Term Debt = 5.60m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.60m USD (from shortTermDebt, last quarter)
Debt = 5.60m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 790.5m USD (928.5m + Debt 5.60m - CCE 143.6m)
Interest Coverage Ratio = -7.26 (Ebit TTM 24.8m / Interest Expense TTM -3.42m)
EV/FCF = -10.93x (Enterprise Value 790.5m / FCF TTM -72.4m)
FCF Yield = -9.15% (FCF TTM -72.4m / Enterprise Value 790.5m)
FCF Margin = -63.67% (FCF TTM -72.4m / Revenue TTM 113.6m)
Net Margin = 24.66% (Net Income TTM 28.0m / Revenue TTM 113.6m)
Gross Margin = unknown ((Revenue TTM 113.6m - Cost of Revenue TTM 760.0k) / Revenue TTM)
Tobins Q-Ratio = 4.99 (Enterprise Value 790.5m / Total Assets 158.3m)
Interest Expense / Debt = 41.85% (Interest Expense 2.34m / Debt 5.60m)
Taxrate = 0.70% (224.0k / 32.1m)
NOPAT = 24.7m (EBIT 24.8m * (1 - 0.70%))
Current Ratio = 3.64 (Total Current Assets 149.2m / Total Current Liabilities 41.0m)
Debt / Equity = 0.05 (Debt 5.60m / totalStockholderEquity, last quarter 107.4m)
Debt / EBITDA = -1.09 (Net Debt -28.6m / EBITDA 26.1m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -28.6m / FCF TTM -72.4m)
Total Stockholder Equity = 63.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.85% (Net Income 28.0m / Total Assets 158.3m)
RoE = 44.49% (Net Income TTM 28.0m / Total Stockholder Equity 63.0m)
RoCE = 36.23% (EBIT 24.8m / Capital Employed (Equity 63.0m + L.T.Debt 5.60m))
RoIC = 39.17% (NOPAT 24.7m / Invested Capital 63.0m)
WACC = 14.11% (E(928.5m)/V(934.1m) * Re(13.94%) + D(5.60m)/V(934.1m) * Rd(41.85%) * (1-Tc(0.01)))
Discount Rate = 13.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 56.57%
Fair Price DCF = unknown (Cash Flow -72.4m)
EPS Correlation: 69.61 | EPS CAGR: 64.06% | SUE: 0.73 | # QB: 0
Revenue Correlation: 20.55 | Revenue CAGR: -27.32% | SUE: -0.76 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-0.36 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=-1299.1% | Growth Revenue=-64.0%